source
- [177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.onclive · 3mo ago↗ source
- Pfizer and Arvinas give disappointing breast cancer drug to RigelPfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. T…Endpoints · 3mo ago↗ source
- FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid SarcomaThe FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.